— Avid Bioservices (NASDAQ: CDMO) reported a second-quarter 2020 loss of $0.03 per share versus a loss of $0.05 per share expected.
— Revenue soared by 80% to $18.3 million versus $14.25 million expected. This was driven by an increase in the number of in-process and completed manufacturing runs as a result of growing demand from a more diversified client base.

— As of October 31, 2019, revenue backlog was about $52 million, a decrease of 16% as compared to the first quarter of fiscal 2020. The company expects to recognize the majority of this backlog within the next twelve months.
— The gross margin increased to 18% from 3% in the prior-year quarter. This was primarily attributed to the increased number of manufacturing runs.
— Looking ahead into fiscal 2020, the company confirmed its revenue outlook in the range of $64 million to $67 million. In contrast, analysts expect revenue of $65.38 million for the full year.
— The company launched expanded process development (PD) facilities and services. Also, it expanded the scope of work with multiple existing customers to increase the number of manufacturing batches and/or scale of production.
Most Popular
DG Earnings Preview: What to look for when Dollar General reports Q3 results
Discount store chain Dollar General Corporation (NYSE: DG) will be reporting third-quarter results next week. Operating nearly 20,000 stores across the US, it is one of the largest supermarket chains
Dollar Tree (DLTR): A few points to note about the discount retailer’s Q3 performance
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) were up over 1% on Thursday. The stock has dropped 13% year-to-date. The discount retailer delivered third-quarter 2023 earnings results that did not
KR Earnings: Key quarterly highlights from Kroger’s Q3 2023 financial results
The Kroger Co. (NYSE: KR) reported its third quarter 2023 earnings results today. Total company sales were $34 billion compared to $34.2 billion for the same period last year. Identical sales
Comments
Comments are closed.